Senestech Stock Today
| SNES Stock | USD 2.19 0.21 8.75% |
PerformanceVery Weak
| Odds Of DistressVery High
|
SenesTech is selling for under 2.19 as of the 16th of March 2025; that is 8.75 percent decrease since the beginning of the trading day. The stock's lowest day price was 2.12. SenesTech has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of December 2016 | Category Basic Materials | Classification Health Care |
SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona. Senestech operates under Specialty Chemicals classification in the United States and is traded on NASDAQ Exchange. The company has 1.03 M outstanding shares of which 83.44 K shares are at this time shorted by private and institutional investors with about 1.24 trading days to cover. More on SenesTech
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
SenesTech Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Joel Fruendt | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Basic Materials, NASDAQ Composite, Health Care, Pharmaceuticals, Specialty Chemicals, Basic Materials (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSenesTech can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand SenesTech's financial leverage. It provides some insight into what part of SenesTech's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SenesTech (SNES) is traded on NASDAQ Exchange in USA. It is located in 23460 North 19th Avenue, Phoenix, AZ, United States, 85027 and employs 25 people. SenesTech is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.26 M. SenesTech conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 1.03 M outstanding shares of which 83.44 K shares are at this time shorted by private and institutional investors with about 1.24 trading days to cover.
SenesTech currently holds about 5.02 M in cash with (6.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41.
Check SenesTech Probability Of Bankruptcy
Ownership AllocationSenesTech has 5.87 % of its outstanding shares held by insiders and 12.51 % owned by institutional holders.
Check SenesTech Ownership Details
SenesTech Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ubs Group Ag | 2024-12-31 | 4.1 K | |
| Tower Research Capital Llc | 2024-12-31 | 1.3 K | |
| Bank Of America Corp | 2024-12-31 | 8.0 | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 0.0 | |
| Sabby Management Llc | 2024-12-31 | 0.0 | |
| Mcadam, Llc | 2024-09-30 | 0.0 |
SenesTech Historical Income Statement
SenesTech Stock Against Markets
SenesTech Corporate Management
| Steven Krause | Ex Marketing | Profile | |
| Paul Palz | VP Controller | Profile | |
| Thomas MBA | CFO, VP | Profile | |
| Nicole Williams | Chief Officer | Profile |
Additional Tools for SenesTech Stock Analysis
When running SenesTech's price analysis, check to measure SenesTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SenesTech is operating at the current time. Most of SenesTech's value examination focuses on studying past and present price action to predict the probability of SenesTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SenesTech's price. Additionally, you may evaluate how the addition of SenesTech to your portfolios can decrease your overall portfolio volatility.